Generation X (now age 46-61) uniquely vulnerable: first post-pension cohort with inadequate savings and decades of financial shocks: Gen X entered workforce 1980s as companies eliminated defined-benefit pensions before 401(k)s widely available — median retirement savings $107,000 won't sustain 25-30+ year retirement — working years hit by 2008 financial crisis, COVID, inflation, tariffs — many took on college debt for kids, serving as caregivers (reducing work/earnings) — nearly 40% expect to retire at age 70+ or not at all.

High anxiety despite reliance: 77% concerned SS won't be there vs. 81% planning to depend on it — widespread misconception about trust fund shortfall: June 2025 AARP poll: 41% will rely on SS (only 17% on pensions) — 2024 Transamerica survey: 77% worried SS won't exist at retirement — over 40% think SS pays zero benefits if trust depleted (actually reduces ~17% in 2034, two years after oldest Gen X reaches full retirement age 67) — only 31% correctly understand benefits continue but reduced.

Real-world response: working longer, claiming early despite smaller benefits, planning without SS entirely: Examples: Kip Corriveau (59) working to 67+, "SS is kind of the base" but worried about cuts; Jennifer Reaves (56) planning retirement without SS factored in, claiming at 62 despite 25% smaller payment; John Quinn (60) never factored SS into ledger, working to 75 — many ask financial advisers to include "haircut" in SS estimates or exclude entirely — skepticism Congress will act before Gen X affected, despite experts saying only "small tweak" needed to stabilize program.

Nine states eliminate state income tax entirely — automatic tax relief for all retirement income: Alaska, Florida, Nevada, New Hampshire, South Dakota, Tennessee, Texas, Washington (capital gains only for high earners), and Wyoming offer automatic tax benefits — no state income taxes on Social Security, pensions, 401(k)s, IRAs, or military retirement — note: these states may levy property taxes or sales taxes to offset lack of income tax revenue.

Seven additional states offer favorable retirement tax treatment without eliminating income tax: Arkansas (exempts $6K/year pension/IRA, no SS tax, no estate tax), Illinois (exempts pensions/401k/IRA/SS/military), Iowa (no tax on retirement income 55+, flat 3.8% tax), Mississippi (exempts retirement plans/SS/military), New Hampshire (no SS/pension tax, repealed interest/dividend tax Jan 2025), Pennsylvania (exempts SS/pensions/retirement distributions), South Carolina (exempts SS and military retirement).

Strategic retirement relocation can significantly reduce tax burden beyond just income taxes: 42 states don't tax Social Security, 37 don't tax military retirement, 16 exempt pensions — combine tax-friendly state residency with strategies like delaying SS to 70, Roth conversions, strategic withdrawals from taxable vs. tax-deferred accounts, charitable giving — RMDs begin at 73, making pre-73 Roth conversions valuable for reducing future tax burden — consider consulting financial advisor on total picture beyond just taxes.

IRA eliminated perverse incentive favoring expensive branded drugs over cheaper generics by increasing plan liability to 60%: Pre-2024, plans preferred high-list/high-rebate brands because federal reinsurance covered 80% above catastrophic threshold — example: branded Copaxone cost plans only $13,187 (17% of cost) vs. generic $21,226 — IRA changed incentives: eliminated coverage gap, increased plan liability, capped out-of-pocket at $2,000 — result: plans shifted to near-universal generic coverage for MS drugs and other conditions, reversing decades of brand dominance.

But IRA created new affordability problems: higher deductibles, narrower formularies, shifted costs to upfront payments: 2025 deductibles 63% higher for MA plans, 22% higher for drug plans despite higher subsidies — plans shifted from fixed copays to percentage-based coinsurance and increased deductibles — only beneficiaries with high annual drug spending reach $2,000 cap (majority don't directly benefit) — narrowing particularly severe for complex diseases like MS where 8 of 11 brand-only drugs have less than 25% formulary coverage.

IRA cost hundreds of billions more than projected; tradeoff between catastrophic drug spending reduction and moderate-spending beneficiary costs: Early evidence shows IRA reduced catastrophic drug costs but shifted financial risk to plans, prompting utilization tightening — moderate drug spending beneficiaries may face higher out-of-pocket costs and premiums vs. pre-IRA — program costs exceeded CBO projections partially due to unexpected Premium Stabilization Demonstration needs — lesson: "when you change who pays, you change what gets covered" and resulting tradeoffs.